Glofitamab with polatuzumab vedotin in relapsed/refractory central nervous system lymphomas. (PubMed, Blood Adv) - Oct 23, 2026 - "These data indicate glofitamab with polatuzumab vedotin is capable of safely inducing deep and rapid clinical remissions in r/r CNSL, including in high-risk histological and molecular subtypes. Future prospective evaluation of the regimen for r/r CNSL is warranted given the unmet need of this population."
Journal • Burkitt Lymphoma • CNS Lymphoma • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology • TP53
|
|
Alex F Herrera; Alexey V Danilov; Avyakta Kallam; Azra Borogovac; Brian Sworder; Geoffrey Shouse; James K Godfrey; Joo Y Y Song; Paolo Lopedote; Tycel J Phillips; Yan Liu
|